logo-loader
viewAcasti Pharma Inc

Acasti Pharma gets new Chinese patent that paves the way for its heart disease therapy

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) Co-Founder and COO Pierre Lemieux tells Proactive Investors it was awarded a second patent in China covering its flagship drug candidate CaPre, an omega-3 phospholipid.

Lemieux says currently in China there is no approved drug like CaPre, where he says obesity and diabetes are problematic.

Quick facts: Acasti Pharma Inc

Price: 0.99 CAD

TSX-V:ACST
Market: TSX-V
Market Cap: $91.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Acasti has 'put its finger on something very interesting' in...

Acasti Pharma Inc (NASDAQ:ACST)(CVE:ACST) COO Pierre Lemieux tells Proactive the last patient completed their final visit in its TRILOGY 1 trial of lead drug CaPre, which treats severe hypertriglyceridemia. Lemieux says the Quebec-based company is on its way to reporting results by the end of...

on 11/26/2019

2 min read